Complement Receptor 1 Expression in Peripheral Blood Mononuclear Cells and the Association with Clinicopathological Features And Prognosis of Nasopharyngeal Carcinoma

  • He, Jian-Rong (State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center) ;
  • Xi, Jing (State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center) ;
  • Ren, Ze-Fang (State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center) ;
  • Qin, Han (State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center) ;
  • Zhang, Ying (State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center) ;
  • Zeng, Yi-Xin (State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center) ;
  • Mo, Hao-Yuan (State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center) ;
  • Jia, Wei-Hua (State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center)
  • 발행 : 2012.12.31


Purpose: Complement receptor 1 (CR1) is induced by Epstein-Barr virus (EBV) and may be a potential biomarker of nasopharyngeal carcinoma (NPC). We conducted the present study to evaluate the association of CR1 expression with clinicopathological features and prognosis of NPC. Methods: We enrolled 145 NPC patients and 110 controls. Expression levels of CR1 in peripheral blood mononuclear cells (PBMCs) were detected using quantitative real-time PCR and associations with clinicopathological features and prognosis were examined. Results: CR1 levels in the NPC group [3.54 (3.34, 3.79)] were slightly higher than those in the controls [3.33 (3.20, 3.47)] (P<0.001). Increased CR1 expression was associated with histology classification (type III vs. type II, P=0.002), advanced clinical stage (P=0.003), high T stage (P=0.017), and poor overall survival (HR, 4.89; 95% CI, 1.23-19.42; P=0.024). However, there were no statistically significant differences in CR1 expression among N or M stages. Conclusion: These findings indicate that CR1 expression in PBMCs may be a new biomarker for prognosis of NPC and a potential therapeutic target.


Complement receptor 1;mRNA expression;NPC;PBMCs;prognosis


  1. Lai HC, Hsiao JR, Chen CW, et al (2010). Endogenous latent membrane protein 1 in Epstein-Barr virus-infected nasopharyngeal carcinoma cells attracts T lymphocytes through upregulation of multiple chemokines. Virology, 405, 464-73.
  2. Li J, Zeng XH, Mo HY, et al (2007). Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy. PLoS One, 2, e1122.
  3. Liew C-C, Ma J, Tang H-C, Zheng R, Dempsey AA (2006). The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med, 147, 126-32.
  4. Markiewski MM, Lambris JD (2009). Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol, 30, 286-92.
  5. Marten A, Buchler MW, Werft W, et al (2010). Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior to CA19.9 and radiology. J Immunother, 33, 219-24.
  6. Medicus RG, Melamed J, Arnaout MA (1983). Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules. Eur J Immunol, 13, 465-70.
  7. Nicholson-Weller A, Klickstein LB (1999). C1q-binding proteins and C1q receptors. Curr Opin Immunol, 11, 42-6.
  8. Paccaud JP, Schifferli JA, Baggiolini M (1990). NAP-1/IL-8 induces up-regulation of CR1 receptors in human neutrophil leukocytes. Biochem Biophys Res Commun, 166, 187-92.
  9. Pascual M, Duchosal MA, Steiger G, et al (1993). Circulating soluble CR1 (CD35). Serum levels in diseases and evidence for its release by human leukocytes. J Immunol, 151, 1702-11.
  10. Sobin LH, Wittekind CH (1997). UICC TNM classification of malignant tumors. Springer-Verlag, Berlin pp 27-30.
  11. Srivastava A, Mittal B (2009). Complement receptor 1 (A3650G RsaI and intron 27 HindIII) polymorphisms and risk of gallbladder cancer in north Indian population. Scand J Immunol, 70, 614-20.
  12. Wagner C, Hansch GM (2006). Receptors for complement C3 on T-lymphocytes: relics of evolution or functional molecules? Mol Immunol, 43, 22-30.
  13. Walport MJ (2001a). Complement. First of two parts. N Engl J Med, 344, 1058-66.
  14. Walport MJ (2001b). Complement. Second of two parts. N Engl J Med, 344, 1140-4.
  15. Yoshizaki T, Sato H, Murono S, Pagano JS, Furukawa M (1999). Matrix metalloproteinase 9 is induced by the Epstein-Barr virus BZLF1 transactivator. Clin Exp Metastasis, 17, 431-6.
  16. Young LS, Rickinson AB (2004). Epstein-Barr virus: 40 years on. Nat Rev Cancer, 4, 757-68.
  17. Zhou X, Temam S, Oh M, et al (2006). Global expression-based classification of lymph node metastasis and extracapsular spread of oral tongue squamous cell carcinoma. Neoplasia, 8, 925-32.
  18. Burczynski ME, Dorner AJ (2006). Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics, 7, 187-202.
  19. Burczynski ME, Twine NC, Dukart G, et al (2005). Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res, 11, 1181-9.
  20. Bushel PR, Heinloth AN, Li J, et al (2007). Blood gene expression signatures predict exposure levels. Proc Natl Acad Sci U S A, 104, 18211-6.
  21. Cao SM, Simons MJ, Qian CN (2011). The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer, 30, 114-9.
  22. Cohen JH, Fischer E, Kazatchkine MD, et al (1987). Expression of CR1 and CR2 complement receptors following Epstein- Barr virus infection of Burkitt's lymphoma cell lines. Scand J Immunol, 25, 587-98.
  23. Ehlenberger AG, Nussenzweig V (1977). The role of membrane receptors for C3b and C3d in phagocytosis. J Exp Med, 145, 357-71.
  24. Erdei A, Isaak A, Torok K, et al (2009). Expression and role of CR1 and CR2 on B and T lymphocytes under physiological and autoimmune conditions. Mol Immunol, 46, 2767-73.
  25. Fingeroth JD, Heath ME, Ambrosino DM (1989). Proliferation of resting B cells is modulated by CR2 and CR1. Imunol Lett, 21, 291-301.
  26. Fischer E, Capron M, Prin L, Kusnierz JP, Kazatchkine MD (1986). Human eosinophils express CR1 and CR3 complement receptors for cleavage fragments of C3. Cell Immunol, 97, 297-306.
  27. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M (2003). Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol, 40, 109-23.
  28. Grigoryev DN, Mathai SC, Fisher MR, et al (2008). Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Transl Res, 151, 197-207.
  29. He JR, Qin H, Ren ZF, et al (2011). MMP-9 expression in peripheral blood mononuclear cells and the association with clinicopathological features and prognosis of nasopharyngeal carcinoma. Clin Chem Lab Med, 49, 705-10.
  30. Iida K, Nussenzweig V (1983). Functional properties of membrane-associated complement receptor CR1. J Immunol, 130, 1876-80.
  31. Jiao XY, Lu MD, Huang JF, Liang LJ, Shi JS (2004). Genomic determination of CR1 CD35 density polymorphism on erythrocytes of patients with gallbladder carcinoma. World J Gastroenterol, 10, 3480-4.
  32. Jurianz K, Ziegler S, Garcia-Schuler H, et al (1999). Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol, 36, 929-39.
  33. Khera R, Das N (2009). Complement Receptor 1: disease associations and therapeutic implications. Mol Immunol, 46, 761-72.

피인용 문헌

  1. Inherited and Acquired Decrease in Complement Receptor 1 (CR1) Density on Red Blood Cells Associated with High Levels of Soluble CR1 in Alzheimer’s Disease vol.19, pp.8, 2018,